MENSA
2014
Mepolizumab Treatment in Severe Eosinophilic Asthma
In 576 patients with severe eosinophilic asthma, subcutaneous mepolizumab 100 mg every 4 weeks reduced exacerbations compared with placebo.
Result
Primary endpoint: Annual exacerbation rate
53% reduction (p<0.001); FEV1 +98 mL.
- Subtopic
- Anti-IL-5 biologic
- Design
- Multicentre phase-3 RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ERS/ATS 2020 Severe Asthma
- Source
- Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.doi 10.1056/NEJMoa1403290
Discussion & critique
Defined SC mepolizumab 100 mg q4wk as the standard dose for severe eosinophilic asthma.